-+ 0.00%
-+ 0.00%
-+ 0.00%

Artelo says oral ART27.13 matches semaglutide weight loss in obese mice study

PUBT·09/16/2026 11:30:55
Listen to the news
Artelo says oral ART27.13 matches semaglutide weight loss in obese mice study
  • Artelo Biosciences reported nonclinical obesity data for oral ART27.13, a peripherally selective dual CB1/CB2 agonist, dated Sept. 16, 2026.
  • In diet-induced obese mice, ART27.13 monotherapy cut body weight by about 20% over four weeks, matching semaglutide.
  • Combination dosing with semaglutide drove about 40% weight loss, roughly double either treatment alone, reaching lean-animal body weight.
  • Weight reduction was mostly fat, about 80% for ART27.13 arms versus about 70% with semaglutide monotherapy.
  • ART27.13 showed no weight or body-composition effect in lean controls, supporting an obesity-state-specific profile and potential combination positioning in GLP-1 regimens.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160730PRIMZONEFULLFEED9827817) on September 16, 2026, and is solely responsible for the information contained therein.